T Troiani
Overview
Explore the profile of T Troiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A, et al.
Ann Oncol
. 2024 Aug;
35(12):1105-1115.
PMID: 39214459
Background: Emerging evidence supports tumor tissue-based comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC). Data on liquid biopsy-based circulating tumor DNA (ctDNA) CGP are scarce and mainly retrospective. Prospective...
2.
Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, et al.
ESMO Open
. 2023 Apr;
8(3):101198.
PMID: 37119788
Background: Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due...
3.
Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al.
Cancer Med
. 2023 Mar;
12(8):9392-9400.
PMID: 36880426
The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR)...
4.
Ciardiello D, Chiarazzo C, Famiglietti V, Damato A, Pinto C, Zampino M, et al.
ESMO Open
. 2022 Aug;
7(5):100567.
PMID: 35994791
Background: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we...
5.
Brancaccio G, Pellerone S, Scharf C, Ronchi A, Iovino F, Napolitano S, et al.
J Eur Acad Dermatol Venereol
. 2022 May;
36(10):e795-e796.
PMID: 35622455
No abstract available.
6.
Troiani T, De Falco V, Napolitano S, Trojaniello C, Ascierto P
ESMO Open
. 2021 Apr;
6(3):100136.
PMID: 33930656
Cutaneous melanoma is the most lethal form of skin cancer and its incidence has been increasing in the past 30 years. Although this is completely resectable in most cases, thicker...
7.
Giunta E, Bregni G, Pretta A, Deleporte A, Liberale G, Bali A, et al.
Cancer Treat Rev
. 2021 Apr;
96:102177.
PMID: 33798955
A few months ago, results from two randomised phase III trials of total neoadjuvant therapy (TNT) in locally advanced rectal cancer were presented (RAPIDO and PRODIGE 23), consistently showing better...
8.
Troiani T, Napolitano S
Ann Oncol
. 2020 Sep;
31(11):1430-1431.
PMID: 32949715
No abstract available.
9.
Ronchi A, Montella M, Cozzolino I, Argenziano G, Moscarella E, Piccolo V, et al.
Eur Rev Med Pharmacol Sci
. 2020 Apr;
24(7):3829-3838.
PMID: 32329859
Objective: Anaplastic lymphoma kinase (ALK) gene has been demonstrated to be rearranged, mutated or amplified in several haematological and solid tumors. Moreover, the use of ALK inhibitors has recently revolutionized...
10.
Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello P, et al.
Ann Oncol
. 2020 Jan;
31(1):30-40.
PMID: 31912793
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment...